ABSTRACT
Objective:To investigate the effect of chemotherapy combined with sorafenib on the prognosis of FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia and to find a more effective treatment.Methods:The clinical data of 60 patients who were newly diagnosed with acute myeloid leukemia and who received treatment in The Second Affiliated Hospital of Qiqihar Medical University from January 2015 to January 2017 were retrospectively analyzed. The patients were divided into three groups according to whether they were positive for FLT3-ITD and the treatment method they used. The observation group (FLT3-ITD-positive, n = 19) were treated with sorafenib based on routine chemotherapy. The control group 1 (FLT3-ITD-positive, n = 21) was treated only with routine chemotherapy. The control group 2 (FLT3-ITD-negative, n = 20) was treated only with routine chemotherapy. After the first and fourth courses of treatment, clinical efficacy was compared among the three groups. Results:After the first course of treatment, the complete remission rate in control group 2 was 50.0% (10/20), which was significantly higher than 15.8% (3/19) in the observation group and 4.8% (1/21) in the control group 1 ( H = 13.39, P < 0.05). After the fourth course of treatment, the complete remission rate in the observation group, control group 2, and control group 1 was 63.2% (12/19), 60.0% (12/20), and 4.8% (1/21), respectively, and the differences were statistically significant ( H = 19.21, P < 0.05). Four-year follow-up results showed that the median survival time in the observation group, control group 1, and control group 2 was 36.63, 24.15, and 45.00 months respectively. The event-free survival in the observation group, control group 1, and control group 2 was 18.00, 9.82, and 24.90 months, respectively. The median survival time and the event-free survival in the control group 2 were significantly longer than those in the observation group and control group 1 ( χ2 = 19.93, 23.04, both P < 0.001). Conclusion:Chemotherapy combined with sorafenib for treating newly-diagnosed FLT3-ITD-positive acute myeloid leukemia can provide comprehensive benefits and have advantages for survival over chemotherapy without sorafenib and chemotherapy alone.
ABSTRACT
Objective To evaluate the clinical effect and safety of gemcitabine plus carboplatin regimen in the treatment of advanced non-small cell lung cancer(NSCLC) in aged patients. Methods 110 cases of aged patients with NSCLC , were divided into GEM group and NVB group according to the patients "options. GEM group received 1 000 mg/m2, GEM at day 1 and 8, and AUC 5 CBP at day 1. NVB group underwent the therapy of 2.5 mg/m2, NVB at day 1 and8,and 80 mg/m2 DDP at day 1 and 3. Both were treated with 21 days as a cycle. Results Overall re-sponse rate was 75.0% in GEM group and 72.0% in NVB group without significant difference( P>0.05). The medi-an survival time(MST) ,disease median response time(DPT) and one year survival rate were similar in two groups( P>0.05). The incidence of adverse reactions was significantly lower in GEM group than in NVB group ( P<0.05 ).Conclusion Gemcitabine plus carboplatin regimen is effective and safe in treatment of advanced non-small cell lung cancer in aged patients
